Brought to you by 
Astex, Novartis ally in developing oncology drugs
28 Aug 2017
Executive Summary
Novartis licensed worldwide development and commercialization rights to Astex's preclinical oral cell cycle inhibitor AT9311, and gets the option to license its AT7519, a Phase I parenteral cell cycle inhibitor. Both compounds are being studied as potential treatments for solid tumors.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Astex, Novartis ally in developing oncology drugs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice